PL2646466T3 - Środki i sposoby do wytwarzania przeciwciał o wysokim powinowactwie - Google Patents

Środki i sposoby do wytwarzania przeciwciał o wysokim powinowactwie

Info

Publication number
PL2646466T3
PL2646466T3 PL11791284T PL11791284T PL2646466T3 PL 2646466 T3 PL2646466 T3 PL 2646466T3 PL 11791284 T PL11791284 T PL 11791284T PL 11791284 T PL11791284 T PL 11791284T PL 2646466 T3 PL2646466 T3 PL 2646466T3
Authority
PL
Poland
Prior art keywords
methods
high affinity
producing high
affinity antibodies
antibodies
Prior art date
Application number
PL11791284T
Other languages
English (en)
Inventor
Tim Beaumont
Mark Jeroen Kwakkenbos
Hergen Spits
Adrianus Quirinus Bakker
Koen Wagner
Original Assignee
Aimm Therapeutics B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aimm Therapeutics B.V. filed Critical Aimm Therapeutics B.V.
Publication of PL2646466T3 publication Critical patent/PL2646466T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60P—VEHICLES ADAPTED FOR LOAD TRANSPORTATION OR TO TRANSPORT, TO CARRY, OR TO COMPRISE SPECIAL LOADS OR OBJECTS
    • B60P1/00—Vehicles predominantly for transporting loads and modified to facilitate loading, consolidating the load, or unloading
    • B60P1/04—Vehicles predominantly for transporting loads and modified to facilitate loading, consolidating the load, or unloading with a tipping movement of load-transporting element
    • B60P1/28—Tipping body constructions
    • B60P1/283—Elements of tipping devices
    • B60P1/286—Loading buckets
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Transportation (AREA)
  • Mechanical Engineering (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
PL11791284T 2010-12-02 2011-12-02 Środki i sposoby do wytwarzania przeciwciał o wysokim powinowactwie PL2646466T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10193562 2010-12-02
US41990910P 2010-12-06 2010-12-06

Publications (1)

Publication Number Publication Date
PL2646466T3 true PL2646466T3 (pl) 2017-09-29

Family

ID=43837992

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11791284T PL2646466T3 (pl) 2010-12-02 2011-12-02 Środki i sposoby do wytwarzania przeciwciał o wysokim powinowactwie

Country Status (15)

Country Link
US (2) US9206247B2 (pl)
EP (1) EP2646466B1 (pl)
JP (1) JP6013356B2 (pl)
CN (1) CN103429615B (pl)
AU (1) AU2011334867B2 (pl)
BR (1) BR112013013573B1 (pl)
CA (1) CA2819070C (pl)
DK (1) DK2646466T3 (pl)
ES (1) ES2626671T3 (pl)
HU (1) HUE033141T2 (pl)
NZ (1) NZ611600A (pl)
PL (1) PL2646466T3 (pl)
PT (1) PT2646466T (pl)
RU (1) RU2585153C2 (pl)
WO (1) WO2012072814A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
AU2006323315B2 (en) 2005-12-09 2014-02-20 Kling Biotherapeutics B.V. Means and methods for influencing the stability of antibody producing cells
US9273118B2 (en) 2009-07-15 2016-03-01 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
ES2626671T3 (es) 2010-12-02 2017-07-25 Aimm Therapeutics B.V. Medios y métodos para producir anticuerpos de alta afinidad
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
WO2015037992A1 (en) * 2013-09-11 2015-03-19 Aimm Therapeutics B.V. Parechovirus specific antibodies
US10825548B2 (en) * 2013-12-02 2020-11-03 Carterra, Inc. Systems and methods of sensing and analyzing antibody blocking interactions
CA2934660C (en) * 2013-12-24 2023-03-14 Aimm Therapeutics B.V. Ex vivo antibody production
JP6747975B2 (ja) * 2014-01-31 2020-08-26 アイム・セラピューティクス・べー・フェー 安定な抗体を産生するための手段及び方法
WO2016077666A1 (en) * 2014-11-14 2016-05-19 Regeneron Pharmaceuticals, Inc. Method for generating high affinity antibodies
CN105296436B (zh) * 2015-11-19 2018-06-08 江南大学 一株二叔丁基对甲酚单克隆抗体杂交瘤细胞株及其应用
CA3045323A1 (en) 2016-12-02 2018-06-07 Juno Therapeutics, Inc. Engineered b cells and related compositions and methods
WO2018205917A1 (en) * 2017-05-08 2018-11-15 Tsinghua University Novel method for producing antibodies
MX2021003779A (es) * 2018-10-02 2021-09-21 Immunome Inc Anticuerpos dirigidos a la epn1.
EP4017530A4 (en) * 2019-08-21 2024-05-08 Board of Regents, The University of Texas System IMMUNE CELLS FOR ADOPTIVE CELL THERAPIES
US12080759B2 (en) * 2021-05-13 2024-09-03 Taiwan Semiconductor Manufacturing Co., Ltd. Transistor source/drain regions and methods of forming the same

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997764A (en) 1987-04-23 1991-03-05 New York University Transformation of human B-lympocytes with Epstein Barr virus and c-myc containing vectors
WO1989008146A1 (en) 1988-02-26 1989-09-08 Worcester Foundation For Experimental Biology Inhibition of htlv-iii by exogenous oligonucleotides
US5866757A (en) 1992-06-02 1999-02-02 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
WO1994007367A1 (en) 1992-09-29 1994-04-14 Apollon, Inc. Anti-viral oligomers that bind polypurine tracts of single-stranded rna or rna-dna hybrids
FI951600L (fi) 1992-10-05 1995-05-10 Hybridon Inc Terapeuttinen HIV:n vastainen oligonukleotidi ja lääkeaine
WO1994017086A1 (en) 1993-01-25 1994-08-04 Apollon, Inc. Gene regulation by targeting putative intramolecular triple helix
US5550019A (en) 1993-05-26 1996-08-27 La Jolla Cancer Research Foundation Methods of identifying compounds which alter apoptosis
US5866755A (en) 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
EP0716570A4 (en) 1993-09-03 1997-12-17 Systemix Inc Genetically Modified Human Hematopoietic Stem Cells and Their Offspring
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US6001558A (en) 1997-06-25 1999-12-14 Ortho Clinical Diagnostics, Inc. Amplification and detection of HIV-1 and/or HIV 2
DE60035515T2 (de) 1999-09-08 2008-04-17 GeneTrol Biotherapeutics, Inc., Oakland Hohe zytokinproduktion mit verbesserter zelllebensfähigkeit
EP1083230A1 (en) 1999-09-10 2001-03-14 Academisch Medisch Centrum Amsterdam Viral replicons and viruses dependent on inducing agents
US7122180B2 (en) 2000-10-23 2006-10-17 Children's Medical Center Corporation DNA vectors containing mutated HIV proviruses
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
ATE515189T1 (de) 2001-12-10 2011-07-15 California Inst Of Techn Verfahren zur herstellung von antigenspezifischen lymphozyten
US20050009180A1 (en) 2001-12-10 2005-01-13 Lili Yang Method for the generation of antigen-specific lymphocytes
NZ534107A (en) 2001-12-18 2007-02-23 Cancer Rec Tech Ltd Creating and maintaining a cell line that produces a constitutively active signal transducer of activation and transcription (CA-STAT) protein
JP4238138B2 (ja) 2001-12-22 2009-03-11 ４−アンチボディ アーゲー 遺伝的に修飾された脊椎動物前駆体リンパ球の生成方法及び異種結合タンパク質の産生を目的としたその使用。
US20040248296A1 (en) 2002-03-20 2004-12-09 Beresford Paul J. HIV therapeutic
AU2002343870A1 (en) * 2002-11-07 2004-06-07 Kumamoto Technology And Industry Foundation Transgenic mammal carrying ganp and utilization thereof
WO2004065418A1 (ja) * 2003-01-20 2004-08-05 Chugai Seiyaku Kabushiki Kaisha 抗pci中和抗体
GB2398783A (en) 2003-02-26 2004-09-01 Antonio Lanzavecchia A method for producing immortalised human B memory lymphocytes
ATE456581T1 (de) 2003-03-14 2010-02-15 Wyeth Corp Antikörper gegen il21-rezeptor und deren verwendung
ATE473016T1 (de) 2003-11-04 2010-07-15 Novartis Vaccines & Diagnostic Verfahren zur behandlung von krebs mit expression des cd40-antigens
DK1692276T3 (da) 2003-11-19 2010-11-01 Us Gov Health & Human Serv Fremgangsmåde til induktion af udvikling og terminal differentiering af hukommelses-B-celler
GB0327384D0 (en) 2003-11-25 2003-12-31 Queen Mary & Westfield College Gene therapy
US20050238626A1 (en) 2004-04-01 2005-10-27 Lili Yang Antigen specific T cell therapy
WO2005123923A2 (en) 2004-06-17 2005-12-29 Wolfgang Hillen Inducer specific tetracycline repressor proteins and methods of use thereof
EP1627563A1 (en) 2004-08-10 2006-02-22 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for producing a stabilized cell of interest
EP1647595A1 (en) 2004-10-15 2006-04-19 Academisch Medisch Centrum bij de Universiteit van Amsterdam Nucleic acids against viruses, in particular HIV
US7393923B2 (en) 2004-11-08 2008-07-01 The Regents Of The University Of California Red-shifted fluorescent proteins mPlum and mRaspberry and polynucleotides encoding the same
EP1894012A2 (en) * 2005-05-18 2008-03-05 Novartis AG Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling
WO2006132524A1 (en) 2005-06-06 2006-12-14 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for generating a t cell against an antigen of interest.
JP4482693B2 (ja) * 2005-08-29 2010-06-16 国立大学法人 岡山大学 抗体産生細胞の特異的選択方法
US8383364B2 (en) 2005-11-17 2013-02-26 Tet Systems Gmbh & Co. Kg Inducible expression systems
AU2006323315B2 (en) 2005-12-09 2014-02-20 Kling Biotherapeutics B.V. Means and methods for influencing the stability of antibody producing cells
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
AU2008218925A1 (en) 2007-02-20 2008-08-28 Anaptysbio, Inc. Somatic hypermutation systems
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
WO2009105150A2 (en) * 2008-01-28 2009-08-27 Thomas Jefferson University Method of making hybrid cells that express useful antibodies
ES2341419B1 (es) 2008-08-14 2011-05-03 Hospital Clinic I Provincial De Barcelona Wnt1 como biomarcador de daño renal.
RU2537264C2 (ru) 2009-04-03 2014-12-27 Медикал Рисерч Каунсил Мутанты индуцируемой активацией цитидиндеаминазы (aid) и способы их применения
CA2768204A1 (en) 2009-07-15 2011-01-20 Aimm Therapeutics B.V. Gram-positive bacteria specific binding compounds
US9273118B2 (en) 2009-07-15 2016-03-01 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
MX338063B (es) * 2009-10-06 2016-04-01 Medimmune Ltd Molecula de union especifica al rsv.
ES2626671T3 (es) 2010-12-02 2017-07-25 Aimm Therapeutics B.V. Medios y métodos para producir anticuerpos de alta afinidad
EP2785737A2 (en) 2011-12-02 2014-10-08 AIMM Therapeutics B.V. Influenza a virus specific antibodies
CA2934660C (en) * 2013-12-24 2023-03-14 Aimm Therapeutics B.V. Ex vivo antibody production

Also Published As

Publication number Publication date
PT2646466T (pt) 2017-06-07
NZ611600A (en) 2015-02-27
RU2585153C2 (ru) 2016-05-27
RU2013130006A (ru) 2015-01-10
US20130331552A1 (en) 2013-12-12
AU2011334867A1 (en) 2013-06-20
JP2014500726A (ja) 2014-01-16
CN103429615A (zh) 2013-12-04
ES2626671T3 (es) 2017-07-25
AU2011334867B2 (en) 2016-10-13
EP2646466B1 (en) 2017-03-29
EP2646466A1 (en) 2013-10-09
HUE033141T2 (en) 2017-11-28
JP6013356B2 (ja) 2016-10-25
US9969795B2 (en) 2018-05-15
BR112013013573A2 (pt) 2016-10-11
CN103429615B (zh) 2018-03-16
US9206247B2 (en) 2015-12-08
CA2819070A1 (en) 2012-06-07
WO2012072814A1 (en) 2012-06-07
BR112013013573B1 (pt) 2021-04-27
CA2819070C (en) 2020-03-10
US20160096881A1 (en) 2016-04-07
DK2646466T3 (en) 2017-06-06

Similar Documents

Publication Publication Date Title
PL2646466T3 (pl) Środki i sposoby do wytwarzania przeciwciał o wysokim powinowactwie
IL250624A0 (en) Anti-fgfr3 antibodies and methods of using them
IL223018A0 (en) Method for preparing antibodies having improved properties
EP2534178A4 (en) THERAPEUTIC PROCEDURES WITH TI-CD200 ANTIBODIES
IL240898A0 (en) Antibodies against a5c and methods of using the antibodies
EP2624066A4 (en) LOADING ELEMENT AND METHOD FOR THE MANUFACTURE THEREOF
GB201115529D0 (en) Antibodies, uses and methods
GB201115280D0 (en) Antibodies, uses and methods
GB201000467D0 (en) Antibodies
EP2569012A4 (en) ANTI-FGFR2 ANTIBODY
IL221371A0 (en) Anti-lrp6 antibodies
IL249501B (en) A process for creating antibodies
PT2542576T (pt) Métodos para rastreio de anticorpos
EP2542706A4 (en) Apparatus and methods for producing direct reduced iron
EP2558587A4 (en) METHOD FOR DISPLAYING ANTIBODIES
GB201020738D0 (en) Antibodies
GB201002238D0 (en) Antibodies
IL222184A (en) Amino-pyridine-n- oxides are converted and methods of preparation
IL219136A0 (en) Anti-hepsin antibodies and methods using same
IL266073B (en) Proteins comprising heterodimeric antibody fc and methods for their preparation
HK1181827A (en) Method for producing improved feathers and improved feathers thereto
GB201005062D0 (en) Antibodies
GB201020751D0 (en) Antibodies